Datroway is an antibody drug conjugate discovered by Tokyo-based pharmaceutical maker Daiichi Sankyo. It is being jointly developed and commercialised with Cambridge, England-based AstraZeneca PLC.

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...

Israeli drug discovery and development company Compugen (Nasdaq: CGEN; TASE: CGEN) today announced changes in its ...

FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo ...

Clever Culture is quietly automating one of pharma’s most unforgiving jobs , turning a regulatory headache into a scalable ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY ® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...

The pharmaceutical company AstraZeneca can move forward with an addition to one of the buildings on its Frederick campus, after getting approval from the city of Frederick’s Planning Commission. The ...

AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus (SLE) on ...

TROPION-Lung17 Clinical Update: What Investors Should Watch in AstraZeneca and Daiichi Sankyo’s Next Lung Cancer Catalyst ...

AstraZeneca PLC (NASDAQ:AZN) operates across global healthcare markets through advanced research pathways, biopharmaceutical ...

(Alliance News) - AstraZeneca PLC on Tuesday said its drug Saphnelo, or anifrolumab, has been approved in the European Union as a new pre-filled pen for systemic lupus erythematosus. The Cambridge, ...

Fosun is joining the fray through its subsidiary Yao Pharma, which has granted Pfizer an exclusive worldwide license to ...